How CA 125 is used in the routine follow-up of ovarian cancer: A survey of 29 Italian hospitals

被引:2
|
作者
Gion, M [1 ]
Barioli, P [1 ]
Ponti, A [1 ]
Torri, V [1 ]
Mione, R [1 ]
Dittadi, R [1 ]
机构
[1] Osped Civile Venezia, Ctr Reg Studio Indicatori Biochim Tumore, I-30122 Venice, Italy
关键词
tumor markers; CA; 125; ovarian cancer;
D O I
10.1159/000030017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor markers are currently monitored on a routine basis, However, their impact on the course of a disease is still under debate, This relative uncertainty leads to a subjective approach to their use, In order to evaluate the range in the pattern of tumor marker application we carried out a survey on the follow-up of patients with ovarian, breast, and colorectal carcinomas, This report concerns only ovarian cancer, Preliminary results showed that the number of markers used, the cutoff point and, probably of major importance, the management of patients with positive tumor marker vary considerably, When evaluating the institutional setting of the surveyed hospitals, a relatively poor interaction between clinicians and the laboratory staff was found, Actually, in about half of the investigated centers, clinical information is not provided to the laboratory staff and methodological aspects are not reported to clinicans, too, The first step to increase the effectiveness of tumor markers is to improve cooperation between persons assaying the markers and those using them, This is a mandatory task in order to both enable the application of recommendations provided by guidelines and to provide the means to verify their rate of acceptance.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 50 条
  • [1] How tumor markers are used in the routine follow-up of breast and colorectal cancer. A survey of 29 Italian hospitals
    Gion, M
    Barioli, P
    Ponti, A
    Torri, V
    Mione, R
    Dittadi, R
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (03): : 124 - 138
  • [2] Use of CA 125 in follow-up of ovarian cancer
    Rustin, G
    Tuxen, M
    LANCET, 1996, 348 (9021): : 191 - 192
  • [3] Follow-Up of Melanoma: A Survey of Italian Hospitals
    Testori, Alessandro
    Chiarion-Sileni, Vanna
    Stanganelli, Ignazio
    Rossi, Carlo Riccardo
    Di Filippo, Franco
    Ridolfi, Ruggero
    Parmiani, Giorgio
    Gandini, Sara
    Soteldo, Javier
    DERMATOLOGY, 2013, 226 : 32 - 38
  • [4] CA-125 IN THE FOLLOW-UP OF PATIENTS WITH OVARIAN-CANCER
    KOELBL, H
    SCHIEDER, K
    NEUNTEUFEL, W
    BIEGLMAYER, C
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1988, 27 (04): : 335 - 342
  • [5] CASA and CA 125 in diagnosis and follow-up of advanced ovarian cancer
    Oehler, MK
    Sütterlin, M
    Caffier, H
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2513 - 2518
  • [6] CA-125 IN THE FOLLOW-UP OF PATIENTS WITH OVARIAN-CANCER
    HALILA, H
    LEHTOVIRTA, P
    STENMAN, UH
    SEPPALA, M
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1988, 67 (01) : 53 - 58
  • [7] How relevant is the CA-125 monitoring for patients with ovarian cancer in the follow-up? Results from a multicenter survey in 1060 patients with ovarian cancer
    Oskay-Ozcelik, G.
    du Bois, A.
    Fasching, P. A.
    Mahner, S.
    Liebrich, C.
    Glass, A.
    Schmidt-Wetzel, S.
    Muenstedt, C.
    Lichtenegger, W.
    Sehouli, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 466 - 466
  • [8] The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer
    deBruijn, HWA
    vanderZee, AGJ
    Aalders, JG
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 1997, 9 (01) : 8 - 13
  • [9] ENDOMETRIAL AND OVARIAN-CANCER FOLLOW-UP WITH CA125 EIA MONOCLONAL
    TORRE, GC
    ROSSO, G
    CALABRESE, A
    FOGLIA, M
    CARO, MT
    PIROVANO, L
    VIGLIERCIO, GP
    RADICI, E
    MAZZOLENI, G
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11): : 1805 - 1805
  • [10] ESGO Statement on the Role of CA/125 Measurement in Follow-Up of Epithelial Ovarian Cancer
    van der Zee, Ate G. J.
    Colombo, Nicoletta
    Gitsch, Gerald
    Reed, Nicolas
    Amant, Frederic
    Cibula, David
    Kesic, Vesna I.
    Kimmig, Rainer
    Lopes, Alberto D. B.
    Markowska, Janina
    Marth, Christian
    Radolakis, Alexander
    Salvesen, Helga
    Vaitkiene, Daiva
    Verheijen, Rene H. M.
    Zola, Paolo
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (01) : 175 - 175